http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007148241-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 |
| filingDate | 2006-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2007148241-A |
| titleOfInvention | COMPOSITION WITH MODIFIED RELEASE, CONTAINING 1 - [(3-HYDROXYADAMANT-1-ILAMINO) ACETYL] Pyrrolidine-2 (S) -CARBONITRIL |
| abstract | 1. A pharmaceutical composition for preparing a tablet, comprising, in one unit dosage form, for example, a tablet, the following ingredients:! (a) a compound as an active ingredient of the formula:! ! where R is substituted adamantyl, and n is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof,! (b) hydroxypropylmethyl cellulose, whose apparent viscosity is between 80,000 cP and 120,000 cP (nominal value 100,000 cP) in a 1% solution,! (c) microcrystalline cellulose and! (d) magnesium stearate. ! 2. The pharmaceutical composition for producing a tablet according to claim 1, including, based on the weight of the composition:! (a) the compound in an amount of from 20 wt.% to 30 wt.%,! (b) hydroxypropyl methyl cellulose in an amount of from 30 wt.% to 50 wt.%,! (c) microcrystalline cellulose in an amount of from 25 wt.% to 35 wt.%, and! (d) magnesium stearate in an amount of from 0.1 wt.% to 3 wt.%. ! 3. The pharmaceutical composition for producing a tablet according to claim 1 or 2, including, based on the weight of the composition:! (a) the compound in an amount of about 25 wt.%,! (b) hydroxypropyl methyl cellulose in an amount of about 40 wt.%,! (c) microcrystalline cellulose in an amount of about 30 wt.% and! (d) magnesium stearate in an amount of about 1 wt.%. ! 4. The pharmaceutical composition for producing a tablet according to claim 3, including lactose. ! 5. The pharmaceutical composition for producing a tablet according to claim 4, in which the lactose content is from 1 wt.% To 8 wt.%. ! 6. The pharmaceutical composition for producing a tablet according to claim 3, further comprising lactose in an amount of about 4 wt.%. ! 7. The pharmaceutical composition for producing a tablet according to claim 1, wherein the compound is 1- [2 - [(5-cyanopyridin-2-yl) amino] ethylamino] a |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115054582-A |
| priorityDate | 2005-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.